- Home
- PYPL vs ALNY Comparison
PYPL vs ALNY Comparison
Compare PYPL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYPL | ALNY |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 39.0B |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | PYPL | ALNY |
|---|---|---|
| Price | $41.15 | $300.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 30 | 28 |
| Target Price | $61.48 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 12.9M | 827.3K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | 35.59 | ★ 206.88 |
| EPS | 1.21 | ★ 2.33 |
| Revenue | ★ $33,172,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $4.78 | $52.67 |
| Revenue Next Year | $4.24 | $31.48 |
| P/E Ratio | ★ $34.40 | $130.06 |
| Revenue Growth | 4.32 | ★ 22.88 |
| 52 Week Low | $38.46 | $283.10 |
| 52 Week High | $79.50 | $495.55 |
Technical Indicators
Market Signals| Indicator | PYPL | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 28.10 | 51.97 |
| Support Level | $38.46 | $299.75 |
| Resistance Level | $46.48 | $331.27 |
| Average True Range (ATR) | 1.13 | 9.35 |
| MACD | -0.19 | 1.45 |
| Stochastic Oscillator | 0.63 | 69.78 |
Price Performance
Historical ComparisonAbout PYPL PayPal Holdings Inc.
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 439 million active accounts at the end of 2025. The company also owns Venmo, a person-to-person payment platform.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.